Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00570986 · ClinicalTrials.gov registry record · Phase 3

A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Phase 3 study of Plaque Psoriasis, sponsored by AbbVie (prior sponsor, Abbott).

Completed
Registry status
Phase 3
Development phase
1,465
Enrollment target
20
Study locations

NCT00570986 is a Phase 3 study of Plaque Psoriasis that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 1,465 participants, above the 383-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (283% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00570986, a Phase 3 study of Plaque Psoriasis, has completed, sponsored by AbbVie (prior sponsor, Abbott).

COMPLETED
Registry status
Phase 3
Development phase
1,465 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine the safety and efficacy of 2 doses of ABT-874 versus placebo in the treatment of subjects with moderate to severe plaque psoriasis.

Conditions Studied

Plaque Psoriasis

Interventions

  • DRUG Placebo
  • BIOLOGICAL ABT-874

Study Locations (20)

California

  • Site Reference ID/Investigator# 6591 - Bakersfield
  • Site Reference ID/Investigator# 6710 - Fresno
  • Site Reference ID/Investigator# 7885 - Irvine
  • Site Reference ID/Investigator# 6872 - Los Angeles
  • Site Reference ID/Investigator# 7669 - Oceanside
  • Site Reference ID/Investigator# 6821 - San Diego
  • Site Reference ID/Investigator# 6832 - San Diego
  • Site Reference ID/Investigator# 7305 - San Diego
  • Site Reference ID/Investigator# 7990 - San Francisco
  • Site Reference ID/Investigator# 6711 - Santa Monica
  • Site Reference ID/Investigator# 8139 - Torrance
  • Site Reference ID/Investigator# 7167 - Vallejo

Alabama

  • Site Reference ID/Investigator# 6579 - Birmingham
  • Site Reference ID/Investigator# 6697 - Birmingham
  • Site Reference ID/Investigator# 7015 - Huntsville

Arizona

  • Site Reference ID/Investigator# 6728 - Scottsdale
  • Site Reference ID/Investigator# 6584 - Tucson

Colorado

  • Site Reference ID/Investigator# 7302 - Denver
  • Site Reference ID/Investigator# 6921 - Longmont

Arkansas

  • Site Reference ID/Investigator# 6696 - Little Rock

Trial Details

FieldValue
Enrollment Target 1,465 participants
Start Date 2007-11
Est. Completion 2009-06
Phase Phase 3

Sponsor

AbbVie (prior sponsor, Abbott)

88 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00570986

The ClinicalTrials.gov registry entry for NCT00570986 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,465 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 383-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (283% higher). The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00570986 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT00570986 about?

NCT00570986 is a clinical study titled "A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis". The purpose of this study is to determine the safety and efficacy of 2 doses of ABT-874 versus placebo in the treatment of subjects with moderate to severe plaque psoriasis.

What is the current status of trial NCT00570986?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,465 participants. The study started on 2007-11. Estimated completion is 2009-06.

What conditions does trial NCT00570986 study?

This clinical trial studies the following conditions: Plaque Psoriasis.

What interventions are being tested in trial NCT00570986?

The interventions under investigation include: Placebo (DRUG), ABT-874 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00570986?

This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00570986 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Plaque Psoriasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Plaque Psoriasis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.